CAROLINE LEIBOWITZ: Open Payments
NPI 1114532173 · OAKHURST, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,790 in 253 payments from 23 companies in 2025. Trend: 2023 $2,086 · 2024 $1,984 · 2025 $3,790
Food & beverage: $3,790
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 45 | $675 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 25 | $458 |
| Janssen Biotech, Inc. | 25 | $452 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $415 |
| Madrigal Pharmaceuticals | 27 | $318 |
| PFIZER INC. | 14 | $262 |
| Aimmune Therapeutics, Inc. | 36 | $189 |
| QOL Medical, LLC | 10 | $188 |
| Ardelyx, Inc. | 9 | $171 |
| GENZYME CORPORATION | 5 | $102 |
Products named: RINVOQ, TREMFYA, XIFAXAN, REZDIFFRA, ENTYVIO, ZENPEP, Sucraid, IBSRELA.
Industry payments across NJ — which companies pay providers there.
